RSU grant to GTCR-affiliated entity via Maravai (MRVI) director

Rhea-AI Filing Summary

CUNNINGHAM SEAN LAURENCE reported acquisition or exercise transactions in this Form 4 filing.

Maravai LifeSciences Holdings reported an equity compensation grant associated with director Sean Laurence Cunningham. He was awarded 46,293 shares of Class A Common Stock in the form of restricted stock units at no cash cost. These units vest in full on the earlier of one year from the May 26, 2026 grant date or the company’s 2027 annual meeting of stockholders. The securities are held for the benefit of a GTCR-affiliated entity, and Cunningham disclaims any pecuniary interest, with reported direct holdings rising to 184,348 shares after the award.

Insider Trade Summary

Net Buyer: 46,293 shares

Net Buy 1 txn

Insider CUNNINGHAM SEAN LAURENCE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	46,293	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 184,348 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
2. F2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Key Figures

RSU grant size: 46,293 shares Grant price: $0.0000 per share Holdings after grant: 184,348 shares +1 more

4 metrics

RSU grant size 46,293 shares Restricted stock units of Class A Common Stock granted May 26, 2026

Grant price $0.0000 per share Equity award with no cash paid by recipient

Holdings after grant 184,348 shares Total Class A Common Stock reported following the RSU award

Vesting condition Earlier of 1 year or 2027 meeting RSUs vest one year from grant or at 2027 annual stockholders’ meeting

Key Terms

restricted stock units, 2020 Omnibus Incentive Plan, pecuniary interest, beneficial owner, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Omnibus Incentive Plan financial

"awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026"

pecuniary interest financial

"The Reporting Person disclaims any pecuniary interest in the securities"

beneficial owner financial

"this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

GTCR-affiliated entity financial

"holds these securities of the Issuer for the benefit of a GTCR-affiliated entity"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/28/2026 - 06:24 PM Learn about SEC filing dates

FAQ

What insider transaction did Maravai (MRVI) report for Sean Cunningham?

Maravai reported that director Sean Cunningham received 46,293 Class A restricted stock units as an equity award. The grant is compensation, carries a zero purchase price, and increases his reported direct holdings to 184,348 shares after the transaction.

When do Sean Cunningham’s new Maravai (MRVI) restricted stock units vest?

The 46,293 restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the 2027 annual shareholder meeting. This single cliff-vesting schedule concentrates settlement around the next annual meeting timeframe.

Who ultimately benefits from the Maravai (MRVI) RSUs reported by Sean Cunningham?

According to the disclosure, Cunningham holds the securities for the benefit of a GTCR‑affiliated entity under that firm’s policies. He disclaims any pecuniary interest, meaning economic benefits from these shares belong to the GTCR‑affiliated entity, not personally to him.

How many Maravai (MRVI) shares does Sean Cunningham report holding after this grant?

Following the restricted stock unit award, Cunningham reports direct ownership of 184,348 shares of Maravai Class A Common Stock. This total includes the 46,293-share grant, which is subject to vesting conditions tied to time and the 2027 shareholder meeting.

Was Sean Cunningham’s Maravai (MRVI) RSU transaction a market purchase or sale?

The transaction is coded as an acquisition through a grant or award, not an open-market trade. Cunningham did not buy or sell shares for cash; instead he received 46,293 restricted stock units as part of an equity compensation arrangement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CUNNINGHAM SEAN LAURENCE

(Last) (First) (Middle)

C/O GTCR, LLC

300 N. LASALLE SUITE 5600

(Street)

CHICAGO ILLINOIS 60654

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/26/2026		A		46,293(1)	A	$0	184,348(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Sean Cunningham	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)